Company profile: Genmab
1.1 - Company Overview
Company description
- Provider of fully human antibody therapeutics for potential cancer treatment, including investigational Rinatabart Sesutecan with promising anti-tumor activity in heavily pretreated ovarian and endometrial cancer patients; offers AI-powered target identification and candidate design, AI-enhanced clinical trial optimization, and collaboration with technology and academic organizations.
Products and services
- AI-Powered Drug Discovery: Machine learning-driven platform that uses cutting-edge AI to streamline target identification and product candidate design for innovative antibody therapeutics
- Optimizing Clinical Trials: AI-enabled framework that enhances clinical trial design and execution, improving patient recruitment and overall trial efficiency
- Rinatabart Sesutecan (Rina-S): Investigational antibody therapeutic demonstrating promising anti-tumor activity in heavily pretreated patients with ovarian and endometrial cancers
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Genmab
Xenikos
HQ: The Netherlands
Website
- Description: Provider of antibody-based immunotherapies, developing a combination of two toxin-loaded anti-T-cell antibodies to quickly reset the immune system in patients with serious immune diseases or transplant rejection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xenikos company profile →
MinervaX
HQ: Denmark
Website
- Description: Provider of a biotechnology solution developing a novel vaccine against Group B Streptococcus (GBS) using a fusion protein shown to elicit protective immunity; offering the AlpN GBS Vaccine candidate designed for pregnant women and older adults to prevent GBS infections and likely protect against many clinically relevant GBS strains.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MinervaX company profile →
Hibiskus Bio
HQ: United States
Website
- Description: Provider of early-stage development of TIR-199, a small-molecule cancer therapy and potent proteasome inhibitor from the syrbactin natural product family, discovered by founders Profs. Pirrung and Bachmann of the University of California, Riverside (UCR) and Michigan.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hibiskus Bio company profile →
InflaRx
HQ: Germany
Website
- Description: Provider of therapeutics for acute and chronic inflammation targeting the C5a/C5aR pathway, including vilobelimab, a monoclonal antibody for chronic inflammatory diseases, oncology and critically ill COVID-19, authorized for emergency use by the FDA in hospitalized adults requiring invasive mechanical ventilation or ECMO, and INF904, an oral C5aR inhibitor in development for chronic spontaneous urticaria and hidradenitis suppurativa.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InflaRx company profile →
Selexis
HQ: Switzerland
Website
- Description: Provider of proprietary technology and highly specialized expertise for mammalian (suspension-adapted CHO-K1) cell line generation, helping translate scientific innovation into life-saving medicines for patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Selexis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Genmab
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Genmab
2.2 - Growth funds investing in similar companies to Genmab
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Genmab
4.2 - Public trading comparable groups for Genmab
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →